---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-070706"
form_type: "8-K"
ticker: "CRNX"
cik: "0001658247"
company_name: "Crinetics Pharmaceuticals, Inc."
filed_at: "2024-03-19T23:59:59+00:00"
generated_at: "2026-06-04T13:27:27.654075+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Crinetics paltusotine meets all endpoints in Phase 3 acromegaly study; NDA planned 2H 2024

## Summary
- Primary endpoint: 56% of paltusotine patients achieved IGF-1 ≤1.0 xULN vs 5% placebo (p<0.0001).
- All secondary endpoints met: IGF-1 change, GH <1.0 ng/mL, and Acromegaly Symptoms Diary score.
- No serious adverse events reported; common TEAEs included diarrhea, headache, arthralgia, abdominal pain.
- Crinetics to submit NDA to FDA in 2H 2024; potential launch in 2025.
- PATHFNDR-2 enrolled 111 untreated acromegaly patients in a 24-week placebo-controlled trial.

## SEC filing metadata
- accession: 0001193125-24-070706
- form_type: 8-K
- ticker: CRNX
- cik: 0001658247
- company_name: Crinetics Pharmaceuticals, Inc.
- filed_at: 2024-03-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658247/000119312524070706/0001193125-24-070706-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658247/000119312524070706/d814079d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-070706
- JSON: https://secwatch.observer/filing/0001193125-24-070706.json
- Plain text: https://secwatch.observer/filing/0001193125-24-070706.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.